Cure rates are 94% to 99% in people infected with genotype 1 (46% of HCV cases). It has also been evaluated for the treatment of infection with other hepatitis C genotypes, and has shown promising results in genotypes 3 and 4 (making up 30% and less than 22% of HCV cases respectively). Resistance NS5A mutations Multiple mutations of HCV replicons are necessary to cause a significant effect in resistance due to multiple mechanisms of action. In general, HCV genotype 1a is less resistant to mutation than genotype 1b. For genotype 1b a single amino acid substitution (e.g. L31V) in the replicon had less than a 100 fold increase in resistance to the<unk>  in Harvoni, while a two amino acid substitution had over a 1000 fold increase in resistance. Genotype 1a had a similar but more substantial increase in resistance with each respective increase in amino acid substitution with resistance associated substitutions at K24R, M28T/V, Q30R/H/K/L, L31M, and or Y93H/N. NS5A polymorphisms also have an effect on viral resistance with the most common resistance-associated amino acid substitutions detected at Q30R, Y93H or N, and L31M in patients with a rapid virological response (RVR). The specific baseline NS5A resistance-associated polymorphisms observed in clinical trials were M28T/V, Q30H, Q30R, L31M, H58P, Y93H, and Y93N in genotype 1a and L28M, A92T, and Y93H in genotype 1b. Patients with multiple baseline NS5A polymorphisms tend to have higher relapse rates when using<unk> . The difference in relapse rates between treatment naive and treatment experience groups with baseline NS5A polymorphisms ranges from 1% after a 12-week regimen and 0% after a 24-week regimen respectively. NS5B mutations A single amino acid substitution S282T contributes to viral resistance and decreases the activity of<unk>  in<unk>  by approximately 2 to 18 fold. Cross resistance No cross resistance was seen in the combination of<unk>  and<unk>  in ION phase 1,2 and, 3 clinical trials as<unk>  was fully active against<unk> -resistance-associated substitutions and vice versa.
Ledipasvir/sofosbuvir
Atazanavir/ritonavir
Sofosbuvir/velpatasvir
Abacavir/lamivudine
Baloxavir marboxil
Atazanavir/cobicistat
Lamivudine/tenofovir
Fosamprenavir